))
Episode 8: Drug Pricing, Valuing Innovation and No Patient Left Behind with Peter Kolchinsky
Manage episode 337444526 series 3381207
A tartalmat a Gunnar Esiason biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Gunnar Esiason vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Biotechnology investor, Peter Kolchinsky, joins the State of Health to talk with Gunnar about drug pricing. The conversation covers the long term view that when drugs go generic without undue delay, the value they provide to society is far greater than the short-run value that cost effectiveness analyses often show, which Peter details in his book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines. Peter also talks about his new non-profit, No Patient Left Behind, of which Gunnar is a part, and why out of pocket costs should be seen as the true barriers between innovative medicines and patients. Peter uses the COVID-19 pandemic as a case study for improving access issues insofar that out of pocket costs were largely eliminated for vaccines. No Patient Left behind is on twitter @NPLB_org and on the web at www.nopatientleftbehind.org
To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy
Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
23 epizódok
Megosztás
